Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5590809 | Multiple Sclerosis and Related Disorders | 2017 | 10 Pages |
Abstract
Nail loss might represent a new, reversible, adverse event associated with teriflunomide treatment. It shares close analogies with hair loss and thinning, known adverse events of teriflunomide. MS specialists should be aware of this possibility and evaluate treatment discontinuation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
L. Mancinelli, P. Amerio, M. di Ioia, V. Di Tommaso, G. De Luca, M. Onofrj, A. Lugaresi,